Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on September 21, 2007 as doi:10.1124/mol.107.040113

Title Page

SUBSTANCE P NEUROKININ 1 RECEPTOR ACTIVATION WITHIN THE DORSAL RAPHE NUCLEUS CONTROLS SEROTONIN RELEASE IN THE MOUSE FRONTAL CORTEX

Bruno P. Guiard, Jean-Philippe Guilloux, Christelle Reperant, Stephen P. Hunt, Miklos Toth, Alain M. Gardier

Univ. Paris-Sud, EA 3544, Fac. Pharmacie, Châtenay-Malabry cedex F-92296, FRANCE: B.P.G, JP.G, C.R, A.M.G.

Deptartment of Anatomy and Developmental Biology, University College London, Gower street, WC1E6BT London, U.K: S.P.H.

Department of Pharmacology, Weill Medical College of Cornell University, New York, New York 10021, USA: M.T.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Copyright 2007 by the American Society for Pharmacology and Experimental Therapeutics.

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Running title page

Running title: Control of Cortical 5-HT Release by Substance P

Statistics of the manuscript:

Pages: 25 (without figures)
Tables: 1
Figures: 4
References: 40/40
Abstract: 232/250
Introduction: 542/750
Results and Discussion: 2100

Nonstandard abbreviations: aCSF: artificial cerebrospinal fluid; AUC: area under the curve; DRN: dorsal raphe nucleus; FC: frontal cortex; NK: neurokinin; MNR: median raphe nucleus; SSRI: selective serotonin reuptake inhibitor; SP: substance P; 5-HT: serotonin; vH: ventral Hippocampus.

Corresponding author

Alain M. GARDIER

[1]Laboratoire de Neuropharmacologie, EA 3544 MJENR

[1]Univ Paris-Sud Fac. Pharmacie, 5, rue J.B Clément,

92296 Châtenay-Malabry Cedex, France

Tel : 33 1 46 83 54 16; Fax : 33 1 46 83 53 55; email: alain.gardier@u-psud.fr

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Abstract

Preclinical studies suggest that Substance P (SP) neurokinin 1 (NK1) receptor antagonists are efficient in the treatment of anxiety and depression. This therapeutic activity could be mediated via stimulation of serotonin (5-HT) neurons located in the dorsal raphe nucleus (DRN), which receive important SP-NK1 receptor immunoreactive innervations. The present study examined the effects of intra-raphe injection of SP on extracellular 5-HT levels in the frontal cortex, ventral hippocampus and DRN by using intracerebral microdialysis in conscious mice. Intra-raphe SP injection dose-dependently decreased cortical 5-HT release while no effects were detected in the ventral hippocampus. Cortical effects were blocked by the selective NK1 receptor antagonist GR205171, and completely dampened in mice lacking NK1 receptors. Furthermore, genetic (in knockout 5-HT_{1A} -/- mice) or pharmacological inactivation of 5-HT_{1A} autoreceptors blocked cortical responses to SP. Contrasting with its cortical effects, intra-raphe SP injection increased 5-HT outflow in the DRN in wild-type mice, this effect being potentiated by a local perfusion of the selective 5-HT_{1A} antagonist, WAY100635. Finally, SP-induced changes in frontal cortex and DRN dialysate 5-HT levels were blocked by the DRN perfusion of the AMPA/kainate ionotropic receptor antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX). These data support the hypothesis that SP-induced over-activation of 5-HT_{1A} autoreceptors within the DRN limits cortical 5-HT release. A better knowledge of the complex relationship between tachykininergic, serotonergic and glutamatergic systems within the DRN might help better understand the pathophysiology and subsequent treatment of depression.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Introduction

Substance P (SP), a small peptide that belongs to the tachykinins family with neurokinin A (NKA) and neurokinin B (NKB) is widely distributed in the brain, specifically in limbic regions and brainstem nuclei such as the dorsal raphe nucleus (DRN) (Froger et al., 2001; Commons et al., 2002; Lacoste et al., 2006). In several species including rodents and humans, SP distribution overlaps with that of its high-affinity NK1 receptor (Ribeiro-da-Silva and Hokfelt, 2000). Recent clinical and preclinical studies have pointed out the potential therapeutic action of SP (neurokinin 1) receptor antagonists in major depressive disorders (Kramer et al., 1998; Chahl, 2006). Data obtained from NK1 receptor knockout mice have suggested that the antidepressant-like action of NK1 receptor inactivation may result, at least in part, from an increase in central 5-HT neurotransmission through functional desensitization of 5-HT_{1A} autoreceptors located in the DRN (Froger et al., 2001). Pharmacological arguments from wild-type mice chronically treated with a NK1 receptor antagonist also favour this hypothesis (Guiard et al., 2005). Interestingly, such a desensitization of somatodendritic 5-HT_{1A} autoreceptors resembles that induced by chronic treatment with selective serotonin reuptake inhibitors (SSRIs) (Blier and De Montigny, 1980; Hjorth et al., 2000). Thus, the enhancement of serotonergic neurotransmission would be a common element in the antidepressant-like activity of both SSRIs and NK1 receptor antagonists.

Given evidence that NK1 receptor antagonists stimulate the DRN-5-HT system, it may be postulated that endogenous SP limits 5-HT release at serotonergic nerve terminals. However, initial *in vitro* electrophysiological

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

recordings suggested that SP excites DRN 5-HT neurons via glutamatergic afferents (Liu et al., 2002). These findings were consistent with intracerebral *in vivo* microdialysis experiments indicating that SP injection into the DRN in conscious rats produces a small, transient increase in hippocampal 5-HT release (by > 30% for 20 min compared to vehicle controls) (Gradin et al., 1992). The latter findings have been challenged recently by *in vivo* electrophysiological data, suggesting that the effects of SP depended on the location of the recording within the DRN, with excitation predominating in the dorsal part of the DRN and inhibition more ventrally (Valentino et al., 2003). Thus, whether 5-HT neurotransmission would be increased or decreased in projection brain regions of the DRN, would depend on the specific DRN sub-region that projects to the serotonergic nerve terminal area studied. Based on their findings, Valentino et al., (2003) have drawn an *in vivo* model of SP regulation of 5-HT neuronal activity. They propose that excitation of DRN 5-HT neurons synaptically linked with glutamate neurons expressing NK1 receptors, allows 5-HT release and subsequent activation of somatodendritic 5-HT_{1A} autoreceptors. However, this theory is limited by the fact that 5-HT releasing properties of SP have yet to be demonstrated. We therefore employed both genetic and pharmacological approaches to clarify the interactions between SP and 5-HT_{1A} autoreceptors. To better define the effects of proximal and distal intra-raphe SP injection on extracellular levels of 5-HT ([5-HT]ext), we performed intracerebral *in vivo* microdialysis studies in awake, freely moving mice with probes implanted either in a brain region containing numerous 5-HT nerve terminals (frontal cortex, ventral hippocampus) or in the vicinity of 5-HT cell bodies in the DRN.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Material and Methods

Animals. Male C57BL/6 wild-type and NK1 receptor knock-out mice were derived from a stock of genotyped animals received from the animal facility of University College London, United-Kingdom. As well, male wild-type and 5-HT_{1A} receptor knock-out mice also raised on a C57BL/6 genetic background were bred in our animal care facility (Univ. Paris XI, France). All animals were matched for age (8-10 weeks old), weight (25-35g) and kept under standard housing conditions. Experiments were conducted in compliance with the guidelines for care of experimental animals (permissions #92-196 to AMG).

Microdialysis procedure. Concentric dialysis probes were stereotaxically implanted under anaesthesia (chloral hydrate: 400 mg/kg, intraperitoneally i.p.) into the frontal cortex (FC), ventral hippocampus (vH) (active length: 1.5 mm) or dorsal raphe nucleus (DRN) (active length: 1.0 mm). Coordinates from Bregma (AP; L; V in mm) were in the FC: 1.6; 1.3; 1.6; vH: -2.8; 3.0; 4 and DRN: -4.5; 0; 3.5. Animals were allowed to recover from surgery overnight, and, were continuously perfused with artificial cerebrospinal fluid (aCSF, in mmol/L: NaCl 147, KCl 3.5, $CaCl_2$ 1.26, $MgCl_2$ 1.2, NaH_2PO_4 1.0; pH 7.4±0.2) the next day. Dialysate samples were collected every 15 min for the FC and vH (flow rate: 1.5 µl/min) and every 30 min for the DRN (flow rate: 0.5 µl/min). Extracellular 5-HT levels were measured using a High Performance Liquid Chromatography system [limit of sensitivity ≈ 1 fmol per sample (signal-to-noise ratio =2)]. In each experiment, after one hour of stabilization, four samples were collected to measure basal 5-HT values (means±SEM). The administration of pharmacological agents occurred at t=0 and subsequent

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

fractions were collected. SP (5-200 ng) was directly infused into the DRN [(0.1 µL/min for 2 min via a microinjector (Harvard Appartus, France)], by means of a silica catheter glued to the microdialysis probe. Both WAY100635 (100 µM: Guilloux et al., 2006) or DNQX (10 µM: Tao et al., 1997) were injected via the probe after their dissolving in the aCSF. The exact probe locations in brains were determined according to Bert et al. (2004).

Drugs. SP was obtained from Neosystem (Strasbourg, France). GR205171 [(N-((2-Methoxy-5-(5-(trifluoromethyl)-1H-tetrazol-1-yl)phenyl)methyl)-2 phenyl -3-piperidinamine) was a gift from GlaxoSmithKline (Harlow, United Kingdom). WAY100635 [(N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl)-N-(2- pyridinyl) cyclohexanecarboxamide trihydrochloride)] and DNQX [6,7-dinitroquinoxaline-2,3-dione] were purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France).

Data analysis and statistics. Baseline levels of 5-HT were calculated by averaging the levels measured in the first four samples collected before treatment. After administration of the treatment, the 5-HT content of individual dialysate samples was measured and expressed as a percentage of the baseline mean. . The summed effects of each treatment over the course were measured by determining the area under the curve (AUC; mean±SEM) values for the amount of 5-HT outflow during the 0-120 min period post-treatment. Comparisons of the effects of the different doses of SP on extracellular 5-HT levels were performed on AUC values by using a one-way ANOVA followed by a Fisher's PLSD *post hoc* test. The overall effects of "drug pre-treatment

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

and treatment" as main factors was assessed by using a two-way ANOVA followed by Fisher's PLSD post hoc test when appropriate. Finally, A Student's t-test was used to compare two experimental groups, in particular the effects of SP *versus* vehicle in NK1 -/- and 5-HT_{1A} -/- mutant mice.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Results and Discussion

Intra-raphe injection of substance P reduced cortical extracellular 5-HT levels.

In NK1 wild-type (+/+) control mice, the intra-raphe (i.r.) injection of SP (50 and 200 ng) dose-dependently reduced extracellular levels of 5-HT in the frontal cortex (Fig. 1A,B). These findings concur with *in vivo* electrophysiological data which found that the neuronal activity of nearly 80% of DRN 5-HT neurons in rats was inhibited by the local microinjection of SP (Valentino et al., 2003). Interestingly, we found that the i.r. injection of the highest dose of SP (200 ng) failed to alter extracellular levels of 5-HT in the ventral hippocampus when compared with the corresponding group of vehicle-treated wild-type mice (AUC values: -0.7 ± 6.2% *vs* 3.1 ± 5.1%, respectively; $P>0.05$). It appears therefore that SP regulates the DRN activity in a region-dependant manner as previously proposed. A corollary of these intriguing findings is that the efferents of the DRN may differentially drive the activity of 5-HT neurons projecting to different forebrain structures, depending on whether these cells are activated or inhibited by SP (Valentino et al., 2005). From our neurochemical data, it can be postulated that the subpopulation of DRN 5-HT neurons projecting to the FC is inhibited by SP. In contrast, the lack of effect of i.r. injection of SP on extracellular 5-HT levels in the ventral hippocampus suggests that the latter region is not innervated by the DRN 5-HT neurons. This is in agreement with previous studies, which provided both anatomical and pharmacological evidence (Molliver, 1987; Kreiss and Lucki, 1991). Another possible explanation would be that the ventral hippocampus receives both types of innervations (i.e., neurons excited and inhibited by SP),

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

leading to a blunted response. Although this would be important to address in future investigations, it is important to emphasize that the precise injection of drugs in mice is technically difficult and we have to consider the possibility that SP diffused outside the DRN injection site. The median raphe nucleus (MRN), an adjacent area expressing NK1 receptors (Saffroy et al., 2003), is a region of interest as it sends serotonergic projections to the hippocampus. Nevertheless, in contrast to the present results, initial observations indicate that the injection of SP into the MRN produces an excitatory effect on 5-HT turnover and likely neurotransmission in the hippocampus (Forchetti et al., 1982) strongly suggesting that in our experimental conditions the diffusion of SP was restricted to the DRN.

Involvement of NK1 receptors in the cortical effect of intra-raphe injection of substance P.

SP preferentially binds to and activates neurokinin 1 (NK1) receptors. However, it is well established that this neuropeptide may act as an agonist on NK2 and NK3 receptor sub-types, albeit with lower affinities (Maggi et al., 1993). Pharmacological and genetic experiments were thus conducted to assess whether the above inhibitory effects of SP on cortical 5-HT release were specifically mediated by NK1 receptors. In NK1 +/+ mice, the i.r. injection of SP (200 ng) did not modify cortical extracellular 5-HT levels when the potent and selective NK1 receptor antagonist GR205171 (30 mg/kg; i.p.) was given 30 min before (Fig. 1C,D). The dose of GR205171 was chosen on the basis of its capacity to block rat brain NK1 receptors *in vivo* (Rupniak et al., 2003). Similar results have been obtained using a genetic approach.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Indeed, in contrast to NK1 +/+ mice, we showed that NK1 -/- mutant mice were insensitive to the i.r. injection of SP (200 ng) on cortical 5-HT release (Fig. 1E,F). It is noteworthy that neither the pharmacological nor the genetic inactivation of NK1 receptors altered basal extracellular levels of 5-HT in the FC of the mice (Table 1; Fig. 1D,F). These results concur with recent microdialysis experiments performed in awake mice (Zocchi et al., 2003; Guiard et al., 2004) suggesting a lack of tonic regulation of 5-HT transmission by SP. Interestingly, NK1 receptor antagonists have been reported to be efficient anxiolytic and antidepressant agents in several animal models (Chahl, 2006). As SP and 5-HT co-exist in a substantial part of the neuronal DRN population in human and rodent brains (Chan-Palay et al., 1978; Sergeyev et al.,1999), it is possible that 5-HT neurons may regulate the release of SP in stressful conditions (Ebner et al., 2004). Thus, the present results demonstrate that an increase in endogenous SP levels in the DRN (mimicked here by its local injection) specifically activates NK1 receptors, subsequently inhibiting cortical 5-HT neurotransmission. Additional work is now required to address how this particular effect of i.r. injection of SP affects depressive-like symptoms such as anhedonia or despair in various animal paradigms. Such studies could further support the hypothesis that the putative antidepressant activity of NK1 receptors antagonists is related, at least in part, to the blockade of SP neurotransmission within the DRN.

Indirect involvement of somatodendritic 5-HT$_{1A}$ autoreceptors in the cortical effects of intra-raphe injection of substance P.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Given that SP was described as an excitatory neuropeptide, we raised the possibility that its neurochemical effects on cortical 5-HT release might indirectly recruit an inhibitory component in the DRN. Since somatodendritic 5-HT_{1A} autoreceptors play that role in the DRN (Hjorth et al., 2000), the i.r. injection of SP was evaluated in 5-HT_{1A} -/- mice. In these mutant mice, SP (200 ng) failed to modify extracellular levels of 5-HT in the FC (Fig. 2A,B). However, by using a genetic approach (e.g., constitutive disruption of 5-HT_{1A} receptors by homologous recombination of the gene), we cannot definitively state whether presynaptic (in the DRN) rather than postsynaptic (in the FC) 5-HT_{1A} receptors were involved in the inhibitory effects of SP on cortical 5-HT release. Indeed, evidence does exist that 5-HT_{1A} autoreceptors located in the prefrontal cortex are involved in a distal control of DRN 5-HT neuronal activity (Celada et al., 2001). In order to determine whether there is a preferential activation of presynaptic 5-HT_{1A} receptors in the SP response, the selective 5-HT_{1A} receptor antagonist WAY100635 was perfused for two hours into the DRN by reverse microdialysis in 5-HT_{1A} +/+ wild-type mice as previously described (Guilloux et al., 2006). In the FC of 5-HT_{1A} +/+ mice, pre-treatment with the selective 5-HT_{1A} receptor antagonist WAY100635 (100 µM, intra-raphe), but not with the vehicle, significantly blocked the effects of SP injection (200 ng) on extracellular levels of 5-HT (Fig. 2C,D). These results are consistent with the findings that both systemic and i.r injection of WAY100635 attenuated the predominantly inhibitory effects of SP on the DRN 5-HT neuronal activity (Valentino et al., 2003). In marked contrast to the effects observed in the FC, we showed here for the first time that the i.r. injection of SP (200 ng) increased extracellular levels of 5-HT in the DRN

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

compared with the vehicle-treated group in 5-HT_{1A} +/+ mice, the latter effect being potentiated by WAY100635 (Fig. 2E,F). The opposite effects of SP on extracellular 5-HT outflow in the DRN and FC appear to be somewhat equivocal. Nevertheless, they allowed anticipating that SP-induced decreases in cortical 5-HT release resulted from an over-activation of inhibitory 5-HT_{1A} autoreceptors in the DRN. Previous studies in rats reported that relatively high extracellular 5-HT concentrations were required in the DRN to reduce forebrain 5-HT release through the activation of 5-HT_{1A} autoreceptors (Romero and Artigas, 1997; Tao and Auerbach, 2000). No direct evidence supporting these observations has been provided in mice. On the contrary, in a recent study, we reported that a two fold decrease in extracellular 5-HT outflow in the DRN was sufficient to trigger an equivalent increase in the FC in mice (Guiard et al., 2004). It therefore seems possible that activation of DRN 5-HT_{1A} autoreceptors in response to SP might contribute to the inhibition of cortical 5-HT release. Interestingly, despite evidence indicating a tonic inhibitory effect of DRN 5-HT_{1A} autoreceptors on 5-HT neuronal activity (Haddjeri et al., 2004), we observed that neither the pharmacological nor the genetic inactivation of 5-HT_{1A} autoreceptors altered the basal extracellular 5-HT levels in the frontal cortex and the DRN (Table 1, Fig. 2B,D). These findings are in agreement with initial microdialysis studies performed in mice at somatodendritic (Bortolozzi et al., 2004; Guilloux et al., 2006) and terminal levels (He et al., 2001; Knobelman et al., 2001a; Guilloux et al., 2006).

Role of excitatory amino acid receptors in the substance P-induced effect.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

The above findings, (i.e. SP-induced inhibition of cortical 5-HT release through an over-activation of DRN 5-HT_{1A} autoreceptors), may occur through a local elevation of endogenous 5-HT. According to Liu and Aghajanian (2002), such an elevation of 5-HT outflow occurring in the DRN could be attributable to a previous increase in glutamate transmission in the DRN. Consistent with this assumption are the observations that the DRN is endowed with a rich population of NK1 receptors especially dense on glutamate interneurons (Commons and Valentino, 2002, Liu et al., 2002, Commons et al., 2003). A last series of experiments was conducted to determine the putative involvement of glutamate in the neurochemical response to i.r. injection of SP. In our experimental conditions, we showed that the glutamate AMPA/Kainate receptor blocker DNQX alone produced a slight but significant decrease in cortical 5-HT release in NK1 +/+ mice. Despite its own effect, DNQX (10 µM, intra-raphe) significantly attenuated the SP-induced decrease in cortical 5-HT levels (Fig. 3A,B). This strongly suggests that the disinhibitory effect of the AMPA/Kainate receptor antagonist could be ascribed to a specific involvement of glutamate in the SP response. In line with this assumption, the increase in 5-HT outflow induced by i.r. injection of SP (200 ng) was also blocked by DNQX (10 µM, i.r.) in the DRN in NK1 +/+ mice (Fig. 3C,D), while DNQX alone had no effect on DRN extracellular 5-HT levels as demonstrated previously (Tao et al., 1997; Tao and Auerbach., 2003). Based on these results, it can be postulated that increased glutamate release in the DRN would occur after i.r. injection of SP. However, it is important to emphasize that the i.r. injection of glutamate receptor agonists enhances the release of 5-HT at both somatodendritic and

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

nerve terminals levels (Tao and Auerbach, 2000), while in the present study the i.r. injection of SP produced opposite effects in the DRN and FC. Since SP-induced stimulation of glutamate transmission in the DRN is a short lasting effect (return to baseline ~10 minutes after injection: Liu et al., 2002), it is possible that we failed to detect any increases in 5-HT cortical release using intracerebral microdialysis. It is also possible that the elevated pool of extracellular 5-HT levels in the DRN of wild-type mice injected with SP did not solely originate from DRN 5-HT neuronal cell bodies or dendrites. Since the DRN receives serotonergic innervations from the other raphe nuclei (Tischler and Morin, 2003), the release of 5-HT may also result from the stimulation of AMPA/Kainate receptors on serotonergic afferents in the DRN (Figure 4). Alternative mechanisms, such as direct activation of NK1 receptors located on the 5-HT cell bodies, could also account for the inhibitory effect of SP on the serotonergic system. This hypothesis is supported by recent evidence showing that almost 30% of rats and mice DRN 5-HT neurons express NK1 receptors (Lacoste et al., 2006). Finally, NK1 receptors have been clearly identified on GABAergic neurons surrounding 5-HT cell bodies in the DRN and their activation might contribute, at least in part, towards SP-induced attenuation of cortical 5-HT neurotransmission.

In conclusion, our neurochemical data support the idea that increased brain SP levels, specifically in the DRN, may represent an important step in the pathophysiology of depression. In these conditions, the potential antidepressant effects of NK1 receptor antagonists (Chahl, 2006) could be related to their capacity to block or prevent the reported effect of SP on

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

cortical 5-HT transmission. However, it is important to mention that despite the great enthusiasm raised by the first placebo-controlled trials, no antidepressant or modest efficacy of NK1 receptor antagonists were reported in subsequent clinical studies, leading several pharmaceutical companies to discontinue their research program in this field (Czeh et al., 2006; Holtzheimer and Nemeroff, 2006). Additional studies are needed to further characterize the real impact of tachykinins on the 5-HT system, as well as the pathophysiology and treatments of depression. In particular, based on the present data, it can be proposed that abnormal SP neurotransmission in the DRN is involved involved in the inadequate response to the selective serotonin reuptake inhibitors (e.g. long delay of action and/or resistance to the treatment) in some patients. Consequently, rather than being used as monotherapy, NK1 receptor antagonists could conceivably be prescribed as augmentation agents in combination with a traditional antidepressant (Ryckmans et al., 2002; Guiard et al., 2004). This should arouse our attention for future clinical investigations.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Acknowledgements: BPG was a recipient of a fellowship from La foundation pour la Recherche Medicale (FRM) during the performance of this work. We are grateful to GlaxoSmithKline for generous gift of the NK1 receptor antagonist GR205171.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

References

Bert L, Favale D, Jego G, Greve P, Guilloux JP, Guiard BP, et al. (2004) Rapid and precise method to locate microdialysis probe implantation in the rodent brain. *J Neurosci Methods* **140:** 53-57.

Blier P, de Montigny C (1980) Effect of chronic tricylic antidepressant treatment on the serotoninergic autoreceptor: a microiontophoretic study in the rat. *Naunyn Schmiedebergs Arch Pharmacol* **314:**123-128.

Bortolozzi A, Amargos-Bosch M, Toth M, Artigas F, Adell A (2004) In vivo efflux of serotonin in the dorsal raphe nucleus of 5-HT1A receptor knockout mice. *J Neurochem* **88:** 1373-1379.

Celada P, Puig MV, Casanovas JM, Guillazo G, Artigas F (2001) Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvement of serotonin-1A, GABA(A), and glutamate receptors. *J Neurosci* **21:** 9917-9929.

Chahl LA (2006) Tachykinins and neuropsychiatric disorders. *Curr Drug Targets* **7:**993-1003

Chan-Palay V, Jonsson G, Palay SL (1978) Serotonin and substance P coexist i, neurons of the rat's central nervous system. *Proc Natl Acad Sci USA* **75:** 1582-1586.

Commons KG, Connolley KR, Valentino RJ (2003) A neurochemically distinct dorsal raphe-limbic circuit with a potential role in affective disorders. *Neuropsychopharmacology* **28:** 206-215.

Commons KG, Valentino RJ (2002) Cellular basis for the effects of substance P in the periaqueductal gray and dorsal raphe nucleus. *J Comp Neurol* **447:** 82-97.

Czeh B, Fuchs E, Simon M (2006) NK1 receptor antagonists under investigation for the treatment of affective disorders. *Expert Opin Investig Drug* **15:** 479-486.

Ebner K, Rupniak NM, Saria A, Singewald N (2004) Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. *Proc Natl Acad Sci U S A* **101:** 4280-4285.

Forchetti CM, Marco EJ, Meek JL (1982) Serotonin and gamma-aminobutyric acid turnover after injection into the median raphe of substance P and D-ala-met-enkephalin amide *J Neurochem*. **38**:1336-1341.

Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C, et al. (2001) 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. *J Neurosci* **21:** 8188-8197.

Gradin K, Qadri F, Nomikos GG, Hillegaart V, Svensson TH (1992) Substance P injection into the dorsal raphe increases blood pressure and serotonin release in hippocampus of conscious rats. *Eur J Pharmacol* **218:** 363-367.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Guiard BP, Froger N, Hamon M, Gardier AM, Lanfumey L (2005) Sustained pharmacological blockade of NK1 substance P receptors causes functional desensitization of dorsal raphe 5-HT 1A autoreceptors in mice. *J Neurochem* **95:** 1713-1723.

Guiard BP, Przybylski C, Guilloux JP, Seif I, Froger N, De Felipe C et al. (2004) Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. *J Neurochem* **89:** 54-63.

Guilloux JP, David DJ, Guiard BP, Chenu F, Reperant C, Toth M et al. (2006) Blockade of 5-HT(1A) Receptors by (+/-)-Pindolol Potentiates Cortical 5-HT Outflow, but not Antidepressant-Like Activity of Paroxetine: Microdialysis and Behavioral Approaches in 5-HT(1A) Receptor Knockout Mice. *Neuropsychopharmacology* **31:** 2162-2172.

Haddjeri N, Lavoie N, Blier P (2004) electrophysiological evidence for the tonic activation of 5-HT(1A) autoreceptors in the rat dorsal raphe nucleus. *Neuropsychopharmacology* **29:** 1800-1806.

Holtzheimer PE 3rd, Nemeroff CB (2006) Advances in the treatment of depression. *NeuroRx* **3:** 42-56.

He M, Sibille E, Benjamin D, Toth M, Shippenberg T (2001) Differential effects of 5-HT1A receptor deletion upon basal and fluoxetine-evoked 5-HT concentrations as revealed by in vivo microdialysis. *Brain Res* **902:** 11-17.

Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB (2000) Serotonin autoreceptor function and antidepressant drug action. *J Psychopharmacol* **14:** 177-185.

Knobelman DA, Hen R, Lucki I (2001) Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse. *J Pharmacol Exp Ther* **298:** 1083-1091.

Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. *Science* **281:** 1640-1645.

Kreiss DS and Lucki I (1994) Differential regulation of serotonin (5-HT) release in the striatum and hippocampus by 5-HT1A autoreceptors of the dorsal and median raphe nuclei. *J Pharmacol Exp Ther* **269:**1268-1279.

Lacoste B, Riad M, Descarries L (2006) Immunocytochemical evidence for the existence of substance P receptor (NK1) in serotonin neurons of rat and mouse dorsal raphe nucleus. *Eur J Neurosci* **23:** 2947-2958.

Liu R, Ding Y, Aghajanian GK (2002) Neurokinins activate local glutamatergic inputs to serotonergic neurons of the dorsal raphe nucleus. *Neuropsychopharmacology* **27:** 329-340.

Maggi CA, Patacchini R, Rovero P, Giachetti A (1993) Tachykinin receptors and tachykinin receptor antagonists. *J Auton Pharmacol* **13:** 23-93.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Molliver ME (1987) Serotonergic neuronal systems: what their anatomic organization tell us about function. *J Clin Psychopharmacol* **7:**3S-23S.

Ribeiro-da-Silva A, Hokfelt T (2000). Neuroanatomical localisation of Substance P in the CNS and sensory neurons. *Neuropeptides* **34:** 256-271.

Romero L, Artigas F (1997) Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. *J Neurochem* **68:** 2593-2603.

Rupniak NM, Carlson EJ, Shepheard S, Bentley G, Williams AR, Hill A et al. (2003). Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608. *Neuropharmacology* **45:** 231-241.

Ryckmans T, Balancon L, Berton O, Genicot C, Lamberty Y, Lallemand B, Pasau P, Pirlot N, Quere L, Talaga P (2002) First dual NK(1) antagonists-serotonin reuptake inhibitor: synthesis and SAR of a new class of potential antidepressants. *Bioorg Med Chem Lett* **12:** 261-264.

Saffroy M, Torrens Y, Glowinski J, Beaujouan JC (2003) Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. *Neuroscience* **116:**761-773.

Sergeyev V, Hokfelt T, Hurd Y (1999) Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. *Neuroreport* **10:** 3967-3970.

Tao R, Auerbach SB (2003) Influence of inhibitory and excitatory inputs on serotonin efflux differs in the dorsal and median raphe nuclei. *Brain Res* **961:** 109-120.

Tao R, Auerbach SB (2000) Regulation of serotonin release by GABA and excitatory amino acids. *J Psychopharmacol* **14:** 100-113.

Tao R, Ma Z, Auerbach SB (1997) Influence of AMPA/kainate receptors on extracellular 5-hydroxytryptamine in rat midbrain raphe and forebrain. *Br J Pharmacol* **121:** 1707-1715.

Tischler RC, Morin LP (2003) Reciprocal serotonergic connections between the hamster median and dorsal raphe nucleus. *Brain Res* **981**: 126-132.

Valentino RJ, Bey V, Pernar L, Commons KG (2003) Substance P Acts through local circuits within the rat dorsal raphe nucleus to alter serotonergic neuronal activity. *J Neurosci* **23:** 7155-7159.

Valentino RJ, Commons KG (2005) Peptides that fine-tune the serotonin system. *Neuropeptides* **39:** 1-8.

Zocchi A, Varnier G, Arban R, Griffante C, Zanetti L, Bettelini L, et al. (2003) Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse. *Neurosci Lett* **345:** 73-76.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Legends for Figures

Figure 1: **Effect of intra-raphe injection of substance P on 5-HT release in the frontal cortex mice.** (A, C, E) Data are means ± SEM of extracellular 5-HT levels expressed as percentages of basal values (arrows show the time of drug injection). (B, D, F) Data are area under the curve (AUC; means ± SEM) values calculated for the amount of 5-HT outflow. (B) One-way ANOVA on AUC values revealed a significant effect of treatment factor in the frontal cortex (FC) [$F_{(3,33)}$=6.1; p<0.01]. A pharmacological (D) and a genetic (F) inactivation of NK1 receptors were used to verify the selectivity of the SP response. (D) Two-way ANOVA on AUC values indicated a significant effect of pre-treatment (vehicle or GR205171: 30 mg/kg; i.p.) [$F_{(1, 31)}$ = 4.7 ; p<0.05], and treatment (vehicle or SP) [$F_{(1, 31)}$ = 14.1 ; p<0.001] factors, but no significant interaction between these two factors [$F_{(1,31)}$ = 2.9 ; p>0.05] in the FC of NK1+/+ mice. (F) A Student's t-test revealed no significant difference between the effect of vehicle and SP (200 ng) on extracellular 5-HT levels in the FC of NK1 -/- mice. *ns*: not statistically significant. **P<0.01 and ***P<0.001 significantly different from vehicle-treated group. ##P<0.01 001 significantly different from vehicle/SP (200 ng)-treated group. The number of determinations (n) and means ± SEM of baseline 5-HT levels expressed as fmol/sample for each experimental group in the FC were: vehicle (n=7; 9.7 ± 0.7), SP 5 (n=11; 7.9 ± 0.9), SP 50 (n=10; 10.6 ± 0.8) and SP 200 (n=11; 9.4 ± 0.6) (Fig 1A); vehicle/vehicle (n=7; 9.7 ± 0.7), GR205171/vehicle (n=11; 10.1 ± 2.1), vehicle/SP 200 (n=11; 8.6 ± 1.2) and GR205171/SP 200 (n=10; 8.9 ± 0.5) (Fig 1C); vehicle (n=7; 10.4 ± 0.7), SP 200 (n=7; 10.8 ± 1.2) (Fig

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

1E). No significant differences were detected in baseline levels between experimental groups for individual experiments.

Figure 2: Effects of genetic and pharmacological inactivation of 5-HT$_{1A}$ receptors on substance P-induced changes in 5-HT outflow in the frontal cortex and dorsal raphe nucleus. (A, C, E) Data are means ± SEM of extracellular 5-HT levels expressed as percentages of basal values (arrows show the time of vehicle or SP injection while the grey line indicates the duration of intra-raphe perfusion of vehicle or WAY100635 through reverse dialysis). (B, D, F) Data are AUC (means ± SEM) values calculated for the amount of 5-HT outflow. (B) A Student's t-test revealed no significant difference between the effect of vehicle and SP (200 ng) on extracellular 5-HT levels in the FC of 5-HT$_{1A}$-/- mice. (D) A two-way ANOVA on AUC 5-HT ext values revealed a significant main effect of pre-treatment (vehicle or WAY100635: 100 µM) [$F_{(1,25)}$=3.8; p<0.05] and treatment (vehicle or SP) [$F_{(1,25)}$=15.6; p<0.001] factors, but no interaction between these two independent variables [$F_{(1,25)}$=1.2; p=0.27] in the FC of 5-HT$_{1A}$ +/+ mice. (F) A two-way ANOVA on AUC 5-HText values revealed a significant main effect of pre-treatment (vehicle or WAY100635) [$F_{(1,24)}$=5.5; p<0.05] and treatment (vehicle or SP) [$F_{(1,24)}$=35.5; p<0.001] factors, but no interaction between these two factors [$F_{(1,24)}$=2.7; p=0.1] in the DRN of 5-HT$_{1A}$ +/+ mice. Differences between groups of mice were determined by Fisher post hoc test. *ns*: not statistically significant. **P<0.01 compared to vehicle-treated mice, #P<0.05 compared to vehicle/SP treated wild-type mice. The number of determinations (n) and means ± SEM of baseline 5-HT levels expressed as fmol/sample for each experimental group in the FC were: vehicle (n=9; 9.8 ±

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

0.7), SP 200 (n=9; 10.4 ± 0.7) (Fig 2A); vehicle/vehicle (n=7; 10.1 ± 0.9), WAY100635/vehicle (n=10; 10.2 ± 0.8), vehicle/SP 200 (n=11; 8.9 ± 1.4) and WAY100635/SP 200 (n=10; 10.9 ± 1.1) (Fig 2C); and in the DRN: vehicle/vehicle (n=5; 13.9 ± 2.1), WAY100635/vehicle (n=5; 16.1 ± 2.5), vehicle/SP 200 (n=8; 14.3 ± 1.7) and WAY100635/SP 200 (n=7; 12.5 ± 1.8) (Fig 2E). No significant differences were detected in baseline levels between experimental groups for individual experiments.

Figure 3: Effects of pharmacological inactivation of AMPA/Kainate receptors on substance P-induced changes outflow in the frontal cortex and dorsal raphe nucleus in wild-type mice. (A,C) Data are means ± SEM of extracellular 5-HT levels expressed as percentages of basal values (arrows show the time of drug injection while the grey line indicates the duration of intra-raphe perfusion of vehicle DNQX through reverse dialysis). (B,D) Data are AUC (means ± SEM) values calculated for the amount of 5-HT outflow. (B) An overall two-way ANOVA on AUC 5-HText values revealed no significant effect of pre-treatment factor (vehicle or DNQX: 10 μM) [$F_{(1,26)}$=0.0002; p=0.9], but a significant effect of treatment factor (vehicle or SP) [$F_{(1,26)}$=9.7; p<0.01] and a significant interaction between these two factors [$F_{(1,25)}$=12.1; p<0.01] in the FC of wild-type mice. (D) An overall two-way ANOVA on AUC 5-HText values revealed no significant effect of pre-treatment factor (vehicle or DNQX) [$F_{(1,20)}$=0.8; p=0.3], but a significant effect of treatment factor (vehicle or SP) [$F_{(1,20)}$=9.5; p<0.01] and a significant interaction between these two factors [$F_{(1,20)}$=4.4; p<0.05] in the DRN of wild-type mice. Differences between groups of mice were determined by Fisher post hoc test. *P<0.05, **P<0.01 and ***P<0.001 compared to vehicle-treated

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

mice, #P<0.05 and ##P<0.01 compared to vehicle/SP treated mice. The number of determinations (n) and means ± SEM of baseline 5-HT levels espressed as fmol/sample for each experimental group in the FC were: vehicle/vehicle (n=7; 10.1 ± 0.9), DNQX/vehicle (n=6; 9.9 ± 1.1), vehicle/SP 200 (n=11; 9.4 ± 0.6) and DNQX/SP 200 (n=6; 8.7 ± 1.1) (Fig 3A); and in the DRN were: vehicle/vehicle (n=5; 13.9 ± 2.1), DNQX/vehicle (n=5; 15.1± 2.7), vehicle/SP 200 (n=8; 14.3 ± 1.7) and DNQX/SP 200 (n=6; 12.9 ± 2.1) (Fig 3C). No significant differences were detected in baseline levels between experimental groups for individual experiments.

Figure 4: Model of substance P regulation of 5-HT neurotransmission. In the DRN, SP activates NK1 receptors located on glutamatergic neurons (1) and produces glutamate release (black circles). (2) Since the DRN receives serotonergic innervations, the enhancement of glutamate release could stimulate 5-HT release (grey circles) through presynaptic glutamate AMPA/Kainate receptors on serotonergic afferents in the DRN [2a]. As well, 5-HT release could result from the activation of AMPA/Kainate receptor located on 5-HT cell bodies [2b]. (3) The excess of extracellular 5-HT levels in the DRN triggers a delayed inhibition of cortical 5-HT release via 5-HT$_{1A}$ autoreceptor over-activation.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

Table 1: Basal 5-HT levels across all wild-type and mutant mice.

	Basal values of 5-HT extracellular concentrations (in fmol/sample)	
	Frontal Cortex	**Dorsal Raphe Nucleus**
NK1 +/+ mice	9.3 ± 0.9 *(n=78)*	ND
NK1 -/- mice	10.6 ± 0.9 *(n=14)*	ND
5-HT1A +/+ mice	9.7 ± 0.8 *(n=68)*	13.7 ± 2.1 *(n=27)*
5-HT1A -/- mice	10.1 ± 0.7 *(n=18)*	ND

Data are means ± SEM of extracellular 5-HT levels expressed as fmol/20 µl in the FC and as fmol/10 µl in the DRN. The numbers of determinations are in parentheses. ND: not determined.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

FIGURE 1

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

FRONTAL CORTEX
NK1 +/+ mice

A

SP or
vehicle

vehicle
SP 5
SP 50
SP 200

Extracellular 5-HT levels
(% of basal values)
150
100
50
0
0 15 30 45 60 75 90 105 120
Time (min)

B

vehicle
SP
5 50 200 ng
AUC for cortical 5-HT
(% of basal values)
20
0
-20
-40
**
***

C

GR205171 or
vehicle

vehicle / vehicle
vehicle / SP 200
GR 205171 / SP 200
GR 205171 / vehicle

Extracellular 5-HT levels
(% of basal values)
150
100
50
0
SP or vehicle
0 15 30 45 60 75 90 105 120
Time (min)

D

vehicle
SP 200 ng
vehicle GR205171 vehicle GR205171
AUC for cortical 5-HT
(% of basal values)
20
0
-20
-40
***
##

FRONTAL CORTEX
NK1 -/- mice



FIGURE 2

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

FRONTAL CORTEX
5-HT1A -/- mice





FRONTAL CORTEX
5-HT1A +/+ mice





DORSAL RAPHE NUCLEUS
5-HT1A +/+ mice





FIGURE 3

Molecular Pharmacology Fast Forward. Published on September 21, 2007 as DOI: 10.1124/mol.107.040113
This article has not been copyedited and formatted. The final version may differ from this version.

FRONTAL CORTEX





DORSAL RAPHE NUCLEUS





Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 23, 2024

Figure 4



arm.aspetjournals.org at ASPET Journals on April 23, 2024